- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
COUNSELING BEFORE PROSTATE CANCER SCREENING 195
Counseling before prostate cancer screening
Discussing the risks and benefits of prostate cancer screening is considered mandatory before offering a PSA and DRE to asymptomatic men. Such counseling is less controversial when evaluating a symptomatic patient, because a diagnosis of prostate cancer could alter the management. However, all patients should be informed when PSA testing is being considered.
The following points should be considered when counseling asymptomatic men:
•Cancer will be identified in up to 5% men screened.
•Screening enables earlier cancer detection and has the potential to decrease mortality rates.
•Early detection and treatment may avoid future cancer–related illness.
•DRE and PSA measurements can have both false-positive and falsenegative results.
•Prostatic biopsy can be uncomfortable and carries a small risk of sepsis or significant bleeding.
•Repeat biopsy may be recommended (PIN, ASAP, or rising PSA).
•Treatment may not be necessary, or may not be curative.
•Aggressive therapy is necessary to realize any benefit from screening if cancer is found based on the screening biopsy.
•Treatment-related morbidity could lead to a reduction in quality of life.
•Active surveillance may be recommended if a low-risk cancer is found.
196 CHAPTER 6 Urological neoplasia
Prostate cancer: clinical presentation
Since the widespread use of serum PSA testing, the majority of patients now have organ-confined disease at presentation. Shown below are the possible presentations, grouped by disease stage.
Localized prostate cancer (T1–2)
•Asymptomatic, detected through screening serum PSA (most common) or incidental digital rectal examination (DRE)
•Lower urinary tract symptoms (LUTS) (probably due to coexisting benign hyperplasia causing bladder outflow obstruction)
•Hematospermia
•Hematuria (probably due to coexisting benign hyperplasia)
•Perineal discomfort (probably due to coexisting prostatitis)
Locally advanced cancer (T3–4)
•Asymptomatic, with screening serum PSA or incidental DRE
•Lower urinary tract symptoms
•Hematospermia
•Hematuria
•Perineal discomfort
•Symptoms of renal failure/anuria due to ureteral obstruction
•Malignant priapism (rare)
•Rectal obstruction (rare)
Metastatic disease (N+, M+)
•Asymptomatic (“occult disease”), with screening serum PSA or incidental DRE
•Swelling of lower limb due to malignant lymphatic obstruction
•Anorexia, weight loss
•Bone pain, pathological fracture
•Neurological symptoms/signs in lower limbs (spinal cord compression)
•Anemia
PROSTATE CANCER: CLINICAL PRESENTATION 197
Box 6.1 A note about DRE
Since most prostate cancers arise in the peripheral, posterior part of the prostate, they may be palpable on DRE. An abnormal DRE is defined by asymmetry, a nodule, or a fixed, “rock hard” mass. Less than 50% of abnormal DREs are associated with prostate cancer, the remainder being benign hyperplasia, prostatic calculi, chronic prostatitis, or posttherapy changes (TURP, biopsy, radiation therapy).
Only 40% of cancers diagnosed by DRE will be organ confined. The fact that an abnormal DRE in the presence of a low PSA carries a 20–30% chance of predicting prostate cancer rules out any suggestion that the DRE could be abandoned as part of our screening approach.
The utility of the DRE in men on 5A-reductase inhibitors is maintained and in some cases may actually be enhanced through the volume effects of reduction in the overall size of the gland.
198 CHAPTER 6 Urological neoplasia
PSA and prostate cancer
See p. 39 for an introduction to the serum PSA test. Until the development of commercial serum PSA assays in the late 1980s, the only serum marker for prostate cancer was acid phosphatase. This was highly specific for prostate cancer metastatic to bone, but lacked sensitivity in detecting less advanced disease and was even normal in >20% patients with bone metastases.
PSA is a glycoprotein produced primarily by the prostatic acini and disruption of the prostatic architecture by disease states appears to allow more PSA to leak into the bloodstream.
Prior to the PSA era, most men with newly diagnosed prostate cancer had advanced and mostly incurable disease. PSA has revolutionized the diagnosis and management of prostate cancer, although its use in screening and early detection remains controversial.
The predictive values of PSA and DRE for diagnosing prostate cancer in biopsies are shown in Table 6.1. The Prostate Cancer Prevention Trial (PCPT) has forever changed our definition of what a “normal” PSA is. A surprising finding in this study was the high prevalence of prostate cancer among men without clinical suspicion for prostate cancer, including men with PSA levels fewer than 4 ng/mL.
AUA PSA Best Practice Policy 2009 no longer recommends a single, threshold value of PSA that should prompt prostate biopsy. The decision should be based primarily on PSA and DRE results, but should take into account multiple factors, including free and total PSA, patient age, PSA velocity, PSA density, family history, ethnicity, prior biopsy history, and comorbidities. In addition to its use as a serum marker for the diagnosis of prostate cancer, PSA elevations may help in staging, counseling, and monitoring prostate cancer patients.
PSA derivatives (see p. 200) are also useful. Here are some examples:
PSA generally increases with advancing stage and tumor volume, although a small proportion of poorly differentiated tumors fail to express PSA. In men taking 5A-reductase inhibitors such as finasteride or dutasteride for benighn prostatic hyperplasia (BPH) or taking finasteride to treat alopecia, the production of PSA will be suppressed by about 50% at 6 months. Therefore, a corrected PSA should be twice the measured value when these drugs are used. This maintains the utility of PSA as a screening tool for prostate cancer detection.
PSA is used, along with clinical (DRE) T stage and Gleason score, to predict pathological tumor staging and outcome after radical treatments, using statistically derived nomograms and tables as noted on p. 208.
•>50% of patients have extraprostatic disease if PSA >10 ng/mL.
•<5% of patients have lymph node metastases and only 1% have bone metastases if PSA <20 ng/mL.
•66% of patients have lymphatic involvement and 90% have seminal vesicle involvement if PSA >50 ng/mL.
PSA AND PROSTATE CANCER 199
•PSA should be virtually undetectable following radical prostatectomy for gland-confined disease (usually < 0.2 ng/mL). A progressive rise in PSA (continuing to rise above 0.5 ng/mL) after radical prostatectomy precedes the development of clinical metastatic disease by a mean time of 8 years.
PSA falls to within the normal range in 80% of patients with metastatic disease on hormone therapy within 4 months; the PSA rises in a mean time of 18 months after starting hormone therapy, signaling progressive hormone refractory (castrate resistant) disease.
PSA is prostate specific, but unfortunately not prostate cancer specific. Other causes of elevated serum PSA include recent instrumentation (cystoscopy, catheterization for retention), prostate surgical intervention (biopsy, TRUP, laser or microwave ablation), urinary tract infection, including acute (NIH I) or chronic (NIH II) bacterial prostatitis.
In the presence of infection or instrumentation, PSA should not be measured until at least 28 days after the event, to avoid a false-positive result. Ideally, PSA should not be requested within 2 days of ejaculation, as a small number of men may have a transient rise. Routine DRE does not appear to cause any significant changes in PSA levels.
Table 6.1 Predictive value of PSA and DRE for biopsy diagnosis of prostate cancer
PSA (ng/mL) |
d0.5 |
0.6–1.0 |
1.1–2.0 |
2.1–3.0 |
3.1–4.0 |
4.1–10 |
>10.0 |
DRE normal |
6.6% |
10% |
17% |
24% |
27% |
27% |
>50% |
DRE abnormal |
— |
15% |
15% |
30% |
30% |
45% |
>75% |
|
|
|
|
|
|
|
|